Protecting healthy tissue from toxic bursts of superoxides in patients with cancer
Standard-of-care radiotherapy for head and neck cancer generates bursts of toxic superoxides, which can damage healthy tissues in the mouth and throat. Patients may experience this tissue damage as pain, redness, and/or sores, a condition called oral mucositis. In its worst grades, known as severe oral mucositis (SOM), patients are unable to eat solid food and/or drink liquids because of the extremely painful mouth sores. SOM’s impact can be debilitating to patients receiving radiation therapy and may impact their ability to receive their full course of radiotherapy.
Galera’s radioprotective dismutase mimetic, avasopasem manganese, was developed to reduce SOM and other radiotherapy-induced toxicities by rapidly and selectivity converting toxic superoxides generated by radiation therapy to hydrogen peroxide, which is less damaging to healthy tissue.
There are currently no drugs approved by the U.S. Food and Drug Administration to reduce radiotherapy-induced SOM in patients with head and neck cancer.
Increase Radiotherapy Anti-Cancer Efficacy
Harnessing the power of hydrogen peroxide to damage cancer cells
Galera’s next-generation selective dismutase mimetic, rucosopasem manganese (rucosopasem), is a radiosensitizer in development to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT), a type of high fraction dose radiotherapy, in patients with lung cancer and pancreatic cancer. Rucosopasem converts the large bursts of superoxide generated by SBRT into bursts of hydrogen peroxide, a compound harmful to cancer cells.
Rucosopasem is undergoing clinical development with the goal of augmenting the anti-cancer efficacy of SBRT in patients with lung cancer and pancreatic cancer. Currently, Galera has two ongoing clinical trials investigating the combination of rucosopasem and SBRT in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer.
Phase 1/2 Study of Rucosopasem in Combination with SBRT for NSCLC
GRECO-1 is a Phase 1/2, randomized, placebo-controlled study of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with early-stage, peripheral or centrally located non-small cell lung cancer (NSCLC).